RSS   Newsletter   Contact   Advertise with us
Post Online Media

enGene appoints Theresa Podrebarac as CMO

enGeneenGene, a life sciences company, announced that Theresa Podrebarac has joined the company as chief medical officer.
Article continues below

READ MORE InMed appoints Eric A. Adams president, CEO, director

Dr. Podrebarac is a 15-year industry veteran with extensive pharmaceutical drug development expertise from large pharma and biotech companies.

Dr. Podrebarac joins enGene from AbbVie where she served as Vice President, Immunology Clinical Development.

At AbbVie, she led the Immunology Therapeutic Council to develop the future vision for the company's portfolio and introduced integrated biomarker techniques and quantitative decision tools to early clinical development.

Previously, Dr. Podrebarac was Vice President of Early Clinical Development and Immunology at Biogen.

Prior to Biogen, she served as Vice President and Head of Rheumatology Global Clincal Development at EMD Serono and provided strategic leadership to the Autoimmunity, Inflammation and Emerging Therapies Unit.

Dr. Podrebarac is a board certified rheumatologist who earned her medical degree from the University of Western Ontario and completed post-doctoral training in T cell immunology at Harvard University and Brigham and Women's Hospital in Boston.



We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy